US LNG exports surge but will buyers in China turn up?
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), a small-cap pharmaceutical company with a market capitalization of $4.41 million, has announced the conversion of preferred stock into common stock by two of its investors, according to a recent 8-K filing with the Securities and Exchange Commission. InvestingPro analysis shows the company maintains strong liquidity with a current ratio of 7.73, indicating robust short-term financial stability. On May 13, 2025, the company received conversion notices from The Sire Group Ltd. and Blue Harbour Asset Management L.L.C-FZ, leading to the issuance of common stock on May 30, 2025.
The Sire Group converted 139,882 shares of Series AA Convertible Preferred Stock into 150,087 shares of common stock. This conversion was executed under the terms of a Securities Purchase Agreement dated September 13, 2023, where Titan had agreed to issue 950,000 shares of Series AA Preferred Stock to Sire Group at $10.00 per share. The conversion rate was determined by the initial conversion price of $0.466, as outlined in the Series AA Certificate of Designations.
Similarly, Blue Harbour converted 79,773 shares of Series B Convertible Preferred Stock into 265,913 shares of common stock. This transaction followed a Securities Purchase Agreement from March 29, 2025, under which Titan agreed to issue 100,000 shares of Series B Preferred Stock to Blue Harbour at $10.00 per share. The conversion rate for the Series B stock was based on an initial conversion price of $3.00, as specified in the Series B Certificate of Designations.
Both conversions were exempt from registration under Section 4(a)(2) of the Securities Act of 1933 and were issued with a standard Rule 144 restrictive legend. The preferred stock agreements include limitations preventing the acquisition of more than 19.99% of Titan’s outstanding common stock or the maximum percentage permissible under Nasdaq rules without shareholder approval.
This information is based on a press release statement from Titan Pharmaceuticals filed with the SEC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.